Skip to main content
logo
Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,310.00
-120.00 (-1.87%)
Last updated: Sep 2, 2026, 2:34 PM KST

Kwang Dong Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
21,82320,96840,48136,96624,17424,019
Depreciation & Amortization
20,53118,05514,53212,90414,01714,110
Loss (Gain) From Sale of Assets
-886.54-7,677-3,0261,964-166.52-38.87
Asset Writedown & Restructuring Costs
2,5902,590----
Loss (Gain) From Sale of Investments
-7,840-7,050-25,399-9,4121,93210,232
Loss (Gain) on Equity Investments
6,21111,441-767.76429.82435.51112.22
Stock-Based Compensation
635.84238.29---17.59
Provision & Write-off of Bad Debts
1,3560.582,421517.29478.81-497.04
Other Operating Activities
6,19213,82810,17414,10315,73110,883
Change in Accounts Receivable
-14,8321,966-12,401-22,48215,134-14,988
Change in Inventory
-21,90815,419-33,422-33,194-16,56815,153
Change in Accounts Payable
15,83321,772-1,309-7,21320,501-2,987
Change in Unearned Revenue
-305.43-97.619.34-40.20.458.4
Change in Other Net Operating Assets
-11,646-9,011-4,141-6,273-12,848-1,134
Operating Cash Flow
17,68682,341-12,153-11,73062,82254,940
Operating Cash Flow Growth
-70.54%---14.35%140.66%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-16,664-29,862-75,730-34,785-25,383-23,795
Sale of Property, Plant & Equipment
1,312992.735,4834,050306.46263.45
Cash Acquisitions
-13,597-13,597----
Divestitures
588.37-----
Sale (Purchase) of Intangibles
-598.9-1,085-1,937-331.65-616.83-651.85
Investment in Securities
-47,405-74,37086,121-14,583-17,896-18,993
Other Investing Activities
331.7811,472-2,395-26,295200.59443.5
Investing Cash Flow
-69,539-102,57812,772-71,831-42,747-42,976

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-105,400568,500264,000119,000116,000
Long-Term Debt Issued
--49,88810,000-22,000
Total Debt Issued
175,488105,400618,388274,000119,000138,000
Short-Term Debt Repaid
--108,934-549,605-205,000-99,000-106,000
Long-Term Debt Repaid
--8,303-25,093-1,657-16,510-11,913
Total Debt Repaid
-189,748-117,237-574,698-206,657-115,510-117,913
Net Debt Issued (Repaid)
-14,260-11,83743,69067,3433,49020,087
Issuance of Common Stock
61,65261,652----
Repurchase of Common Stock
--364.46-4,067-6,235--
Dividends Paid
-4,966-3,928-4,008-4,108-4,108-4,108
Other Financing Activities
-229.92-6.471,1501,010-10.5-85.54
Financing Cash Flow
42,19645,51736,76558,010-628.2615,894

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
735.57-477.371,461-657139.361,226
Miscellaneous Cash Flow Adjustments
-0-000-00
Net Cash Flow
-8,92124,80238,845-26,20819,58729,084

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
1,02252,479-87,883-46,51537,43931,145
Free Cash Flow Growth
----20.21%77.30%
Free Cash Flow Margin
0.06%3.16%-5.36%-3.07%2.61%2.33%
Free Cash Flow Per Share
22.411304.16-2194.85-1149.35911.36757.27
Levered Free Cash Flow
45,827101,739-139,015-58,70135,40759,535
Unlevered Free Cash Flow
52,945108,617-132,594-54,38637,74161,125

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
10,40110,56911,6517,5063,7482,369
Cash Income Tax Paid
16,5448,78113,59810,36613,69211,370
Change in Working Capital
-32,85930,049-51,254-69,2016,220-3,898